Page 851 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

Index 829

Malignant tumor Mast cell tumor, 19, 382–403, 462 Melanoma (Continued)
benign tumor versus, 63 characteristics of, 142 etiology of, 367
c-kit mutations in, 148
fine-needle aspiration of, 141f
characteristics of, 63
VetBooks.ir histologic features of, 65t definition of, 382 gingival, 370, 370f
histochemical stains for, 71t
nomenclature for, 64t
exon 8/11 duplication in, 148
paraneoplastic syndromes and, 98 features of importance and grades for, 68t lingual, 370f
types of, 63 fine-needle aspiration of, 128f, 131f metastasis of, 368
Malnutrition, cancer and, 98 gastrointestinal ulceration and, 98 molecular characterizations of, 367
Mammalian target of rapamycin (mTOR), histochemical stains for, 71t pathology of, 367
canine osteosarcoma and, 526 immunohistochemical markers/panels for, prognosis of, 368
Mammary adenocarcinoma, fine-needle 72t–73t sites for, 368
aspiration of, 134f metastasis and, 142 staging for, 368–369
Mammary cancer mistaken diagnosis of, 142 treatment of, surgery, 369–370
canine, 17–18 Mastinib (Kinavet), 262–263 Meloxicam, 293t–294t
case-control studies for, 92 Mastocytic mast cell tumor, 394 Melphalan, 184
feline, 18 Mastocytosis, 382 for oral melanoma, 374–375
obesity and, 302 Matrical carcinoma, 359 Meningioma
Mammary gland, lymphatic drainage of, 607 Matrix and metalloprotease, 52–53 intracranial, 658t
Mammary gland carcinoma Matrix metalloproteinase (MMP) inhibitor, 264 in spinal cord, 666t
features of importance and grades for, 68t Matrix metalloproteinases (MMPs), 233, 545 MER. see Maintenance energy requirement
grading of Matrix protease, 52–53 Merkel cell, 360
criteria for, 610t Maxillary oral melanoma, 375f Merkel cell carcinoma, 360
histologic score, 610t Maxillectomies, 439t Mesenchymal hamartoma, 677
inflammatory, in dog, 607f Maximum tolerated dose (MTD), 182–183 Mesenchymal invasion, 52
lymphoscintigraphy for, 607f definition of, 341–342 Mesenchymal stem cell, prodrug cancer gene
Mammary gland tumor, 604–625 phase I trial and, 340–341 therapy and, 256
adjuvant chemotherapy for, prognostic MCE. see Multiple cartilaginous exostosis Mesenchymal tumor
factors and indications for, 614t MCL. see Mantle cell lymphoma as benign/malignant, 64t
characteristics of, 133–134 M-component disorder, 102 cell characteristics in, 138–139
epidemiology of, 604 MDM2, canine osteosarcoma and, 525 with cells in dense aggregates, 141
as preventable, 604–605 MDR. see Multidrug resistant with multinucleated cells, 141
risk factors for, 604–605 MDSC. see Myeloid-derived suppressor cell with round/oval cells, 140–141
age, 604 Mechlorethamine, 190 bone origin tumors as, 140
breeds and genetic susceptibility, 605 Median survival time (MST) chondrocytic tumors and, 140–141
hormonal exposure, 604–605 for digital melanoma, 368 synovial cell tumors as, 141
surgical treatment for for liposarcoma, 408f with spindle-shaped/stellate cells
disease-free interval, 611 for mast cell tumors, 385–386 adipose tissue tumors as, 139
excision recommendations, 611 for oral melanoma, 368 fibroblast tumors as, 138–139
systemic treatment for, 613–614, 615t for prostate cancer, 634 perivascular wall/nerve sheath tumors
chemotherapy, 614 for urinary bladder tumors, 648–649 as, 138
hormonal therapy, 613–614 Medical therapy smooth muscle/stroma tumors as, 139
Mammary neoplasm for canine insulinoma, 584 striated muscle tumors as, 140
as benign for canine pituitary-dependent vascular endothelium tumors as,
in cats, 617 hypercortisolism, 567 138–139
in dogs, 608 for feline acromegaly, 571 tissues, 137–141
as malignant Medium-sized syringe, 127 types of, 598
in cats, 617 Medullary tumor, 137 Mesenchymal-epithelial transition (MET), 53
in dogs, 608–610 Megavoltage photon, 209 Mesenchymoma, 405t
Mandibular mass, 121f Megavoltage radiation Mesothelioma, 784–785
Mandibulectomy, 439t effects of, 215 asbestos exposure and, 17
for bone tumors, 541 equipment, 215 comparative aspects, 787
for osteosarcoma, 440f, 444 Meiosis, 36 diagnostic techniques and workup,
Mantle cell lymphoma (MCL), 146, 700t Melanocyte neoplasm, 72t–73t 785–786, 786f
Marginal excision, 158, 168 Melanocytic tumor, 141 history and clinical signs, 785, 785f
Marginal wound, 167t Melanocytoma, 141 incidence and risk factors, 784–785
Marginal zone lymphoma (MZL), 700t Melanoma, 367–381 pathology and natural behavior, 785
Masitinib amelanotic, 369f treatment and prognosis, 786–787
approval of use for, 345 antigen, 54 Messenger RNA (mRNA)
clinical trial for mast cell tumors biologic behavior for, 367–368 definition/expression of, 151
and, 393 of caudal dental arcade, 371f quantification of, 153
Massage, 335–336 surgical margins for, 371f MET. see Mesenchymal-epithelial transition
Masson trichrome, 71 as conjunctival tumor, 675 MET proto-oncogene, 526, 533